Keytruda

This page shows the latest Keytruda news and features for those working in and with pharma, biotech and healthcare.

Roche gets FDA nod for Tecentriq in small cell lung cancer

Roche gets FDA nod for Tecentriq in small cell lung cancer

without competition from other checkpoint inhibitors, particularly Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) which is dominating the NSCLC category.

Latest news

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    1 inhibitor that brought in a respectable $6.7bn year, but trailed behind Keytruda and its full year earnings of $7.2bn. ... The PD-1/PD-L1 class is a crowded one and Keytruda’s dominance hasn’t scared off new players from entering the field.

  • Keytruda adds another NSCLC approval in Europe Keytruda adds another NSCLC approval in Europe

    Squamous NSCLC completes first-line dominance. The European Commission has granted MSD's Keytruda approval in another major lung cancer setting. ... With this approval, more patients with non-small cell lung cancer may have the opportunity to benefit

  • Celgene’s Abraxane fails pancreatic cancer trial Celgene’s Abraxane fails pancreatic cancer trial

    Celgene picked up the first of these last October when Abraxane was cleared alongside Merck &Co/MSD’s Keytruda (pembrolizumab) for frontline metastatic squamous non-small cell lung cancer. ... for a breast cancer indication – and in September, the

  • Tecentriq gains first IO approval in triple negative breast cancer Tecentriq gains first IO approval in triple negative breast cancer

    A coup for Roche in IO field dominated by Keytruda. Roche has stolen a march on market leader Keytruda by gaining the first immuno-oncology approval in triple negative breast cancer. ... This is based on Keytruda’s tally of 14 FDA approvals, while the

  • Tecentriq combo gains European NSCLC approval Tecentriq combo gains European NSCLC approval

    The approval will help Tecentriq compete with Merck Sharp &Dohme’s Keytruda, which has emerged as the out-and-out leader in lung cancer immunotherapy, thanks to a string of strong ... However Tecentriq is still trailing Keytruda in the vital first line

More from news
Approximately 118 fully matching, plus 185 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast. ... On 28 December, Keytruda gained FDA clearance for use in Merkel cell carcinoma.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1 inhibitor Keytruda (pembrolizumab) was backed for cancers harbouring a biomarker known as microsatellite instability-high (MSI-H). ... Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    of this include recent deals on CAR-T therapies, plus a new expansion in the use of Keytruda in lung cancer, announced late last year.

  • Is China ready for a pharmaceutical gold rush?

    Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels. ... In light of recent clinical data, Keytruda is widely regarded as the better of the two checkpoint inhibitors in lung cancer.

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.